Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 1/7/2020
SIETES contiene 93059 citas

 
 
 1 a 20 de 253 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]
2. Cita con resumen
Brownlee S, Garber J. Overprescribed: High cost isn’t America’s only drug problem. STAT Daily Recap 2019:2 de abril. [Ref.ID 103070]
7. Cita con resumen
Habibi R, Lexchin J, Mintzes B, Holbrook A. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. Br J Clin Pharmacol 2017;83:2549-56. [Ref.ID 102116]
9. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
10.Enlace a cita original
Anónimo. Armodafinil for sleep disorders. Australian Prescriber 2016;39:221. [Ref.ID 101022]
12. Cita con resumen
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189. [Ref.ID 100605]
13. Cita con resumen
Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]
14. Cita con resumen
Chinthapalli K. The billion dollar business of being smart. BMJ 2015;351:h4829. [Ref.ID 99542]
15. Cita con resumen
Avorn J, Sarpatwari A, Kesselheim AS. Forbidden and permitted statements about medications - Loosening the rules. N Engl J Med 2015;373:967-73. [Ref.ID 99432]
16. Cita con resumen
Roehr B. Court rules that FDA cannot restrict off-label marketing. BMJ 2015;351:h4367. [Ref.ID 99403]
17. Cita con resumen
Ornstein C, Jones RG. Vying for market share, companies heavily promote ‘me too’ drugs. ProPublica 2015:7 de enero. [Ref.ID 98702]
18. Cita con resumen
Anónimo. Analysis: drug companies increasingly marketing to hospital administrators. DIA Daily 2014:25 de septiembre. [Ref.ID 97956]
19.Tiene citas relacionadas Cita con resumen
Steinbrook R. Should medical journal publish sponsored content?. BMJ 2014;348:g352. [Ref.ID 97341]
Seleccionar todas
 
 1 a 20 de 253 siguiente >>